$912 Million is the total value of SECTORAL ASSET MANAGEMENT INC's 68 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 46.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FOLD | Buy | AMICUS THERAPEUTICS | $51,219,000 | +24.9% | 3,405,541 | +19.5% | 5.62% | +9.6% |
| LJPC | Buy | LA JOLLA PHARMACEUTICAL | $33,598,000 | +22.2% | 1,128,219 | +32.1% | 3.68% | +7.2% |
| BMRN | Buy | BIOMARIN PHARMAC INC | $32,258,000 | +39.9% | 397,903 | +53.9% | 3.54% | +22.8% |
| AERI | Buy | AERIE PHARMACEUTICALS | $29,220,000 | +32.6% | 538,618 | +46.0% | 3.20% | +16.4% |
| JNJ | Buy | JOHNSON & JOHNSON | $28,314,000 | -5.5% | 220,948 | +3.1% | 3.10% | -17.0% |
| CELG | Buy | CELGENE CORP | $27,310,000 | +12.9% | 306,130 | +32.0% | 2.99% | -1.0% |
| SRPT | Buy | SAREPTA THERAPEUTICS | $24,279,000 | +82.6% | 327,698 | +37.1% | 2.66% | +60.2% |
| EXAS | Buy | EXACT SCIENCES CORP | $23,151,000 | +129.0% | 574,049 | +198.3% | 2.54% | +101.0% |
| KTWO | Buy | K2M GROUP HOLDINGS | $23,141,000 | +10.4% | 1,221,160 | +4.9% | 2.54% | -3.1% |
| UNH | Buy | UNITEDHEALTH GRP INC | $19,731,000 | +8.0% | 92,203 | +11.2% | 2.16% | -5.3% |
| MDT | Buy | MEDTRONIC PLC | $18,017,000 | +22.9% | 224,600 | +23.7% | 1.98% | +7.8% |
| CLVS | Buy | CLOVIS ONCOLOGY | $16,938,000 | +36.4% | 320,799 | +75.7% | 1.86% | +19.7% |
| ARRY | New | ARRAY BIOPHARMA INC | $16,837,000 | – | 1,031,650 | +100.0% | 1.85% | – |
| GILD | New | GILEAD SCIENCES INC | $15,455,000 | – | 205,000 | +100.0% | 1.70% | – |
| LLY | Buy | ELI LILLY & CO | $14,089,000 | +1.6% | 182,100 | +10.9% | 1.54% | -10.8% |
| TSRO | Buy | TESARO INC | $12,871,000 | +324.4% | 225,260 | +515.5% | 1.41% | +272.3% |
| PRAH | New | PRA HEALTH SCIENCE | $12,490,000 | – | 150,560 | +100.0% | 1.37% | – |
| UMRX | New | UNUM THERAPEUTICS | $12,016,000 | – | 1,081,545 | +100.0% | 1.32% | – |
| PTCT | Buy | PTC THERAPEUTICS | $11,850,000 | +90.6% | 437,934 | +17.5% | 1.30% | +67.2% |
| ALDR | New | ALDER BIOPHARMACEUTICAL | $10,968,000 | – | 863,600 | +100.0% | 1.20% | – |
| ALXN | New | ALEXION PHARM INC | $10,700,000 | – | 96,000 | +100.0% | 1.17% | – |
| GKOS | New | GLAUKOS CORP | $10,149,000 | – | 329,199 | +100.0% | 1.11% | – |
| BMY | New | BRISTOL MYERS SQUIBB | $9,690,000 | – | 153,200 | +100.0% | 1.06% | – |
| ESPR | Buy | ESPERION THERAPEUTICS | $9,581,000 | +523.8% | 132,468 | +467.7% | 1.05% | +446.9% |
| MOH | Buy | MOLINA HEALTHCARE | $8,773,000 | +118.9% | 108,070 | +106.8% | 0.96% | +92.0% |
| NVRO | New | NEVRO CORP | $8,442,000 | – | 97,400 | +100.0% | 0.93% | – |
| ADMS | New | ADAMAS PHARMACEUTI | $8,397,000 | – | 351,320 | +100.0% | 0.92% | – |
| HRC | Buy | HILL-ROM HLDS INC | $7,673,000 | +31.1% | 88,200 | +27.0% | 0.84% | +15.0% |
| VRAY | Buy | VIEWRAY INC | $7,329,000 | -16.5% | 1,139,863 | +20.3% | 0.80% | -26.6% |
| VRTX | Buy | VERTEX PHARMACEUTICALS | $6,831,000 | +24.2% | 41,915 | +14.2% | 0.75% | +9.0% |
| INCY | Buy | INCYTE CORPORATION | $6,603,000 | +79.0% | 79,245 | +103.5% | 0.72% | +57.0% |
| MDGL | Buy | MADRIGAL PHARMACEUTICALS | $5,915,000 | +74.9% | 50,649 | +37.4% | 0.65% | +53.4% |
| SAGE | Buy | SAGE THERAPEUTICS | $5,251,000 | +85.4% | 32,600 | +89.5% | 0.58% | +62.7% |
| FIXX | New | HOMOLOGY MEDICINES | $4,208,000 | – | 225,000 | +100.0% | 0.46% | – |
| RCKT | New | ROCKET PHARMACEUTICA | $4,053,000 | – | 216,158 | +100.0% | 0.44% | – |
| OBSV | Buy | OBSEVA SA | $3,907,000 | +89.4% | 289,507 | +36.9% | 0.43% | +65.9% |
| Buy | INTEC PHARMA LTD JER | $2,854,000 | +56.1% | 451,252 | +27.1% | 0.31% | +37.3% | |
| AVXS | New | AVEXIS INC | $2,734,000 | – | 22,120 | +100.0% | 0.30% | – |
| SVRA | Buy | SAVARA INC | $2,512,000 | +5.8% | 273,000 | +70.6% | 0.28% | -7.4% |
| SBPH | Buy | SPRING BK PHARMACEUTICALS | $2,025,000 | +22.1% | 131,656 | +6.7% | 0.22% | +7.2% |
| CMTA | Buy | CLEMENTIA PHARMACEUTICALS | $1,700,000 | +19.0% | 112,213 | +49.0% | 0.19% | +3.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOMARIN PHARMAC INC | 42 | Q3 2023 | 6.7% |
| PTC THERAPEUTICS INC | 42 | Q3 2023 | 2.7% |
| DR REDDYS LABS LTD | 42 | Q3 2023 | 2.0% |
| GILEAD SCIENCES INC | 38 | Q3 2023 | 8.4% |
| INCYTE CORPORATION | 38 | Q3 2023 | 5.2% |
| VERTEX PHARMACEUTICL | 38 | Q3 2023 | 6.0% |
| AMICUS THERAPEUTICS INC | 37 | Q3 2023 | 6.6% |
| PFIZER INC | 35 | Q3 2023 | 6.3% |
| MERCK & CO. INC | 34 | Q3 2023 | 6.4% |
| MEDTRONIC PLC | 33 | Q3 2023 | 4.4% |
View SECTORAL ASSET MANAGEMENT INC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aprea Therapeutics, Inc. | February 12, 2021 | 163,681 | 0.8% |
| LA JOLLA PHARMACEUTICAL CO | February 13, 2020 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 13, 2018 | 1,426,862 | 4.4% |
| Advaxis, Inc. | February 10, 2017 | 690,074 | 1.7% |
| AMICUS THERAPEUTICS INC | February 10, 2017 | 5,100,198 | 3.6% |
| OncoMed Pharmaceuticals Inc | February 12, 2016 | ? | ? |
| IRONWOOD PHARMACEUTICALS INC | February 13, 2015 | ? | ? |
| SEQUENOM INC | February 12, 2014 | ? | ? |
| INCYTE CORP | February 11, 2014 | 1,185,260 | 0.7% |
| INTERMUNE INC | February 11, 2014 | ? | ? |
View SECTORAL ASSET MANAGEMENT INC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-02-13 |
| SC 13G | 2023-02-13 |
| 13F-HR | 2023-02-10 |
| 13F-HR | 2022-11-10 |
View SECTORAL ASSET MANAGEMENT INC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.